Please check your internet connection and try again.
# Piperacillin-Tazobactam
## Overview
Piperacillin-tazobactam is a combination beta-lactam antibiotic and beta-lactamase inhibitor, effective against a broad spectrum of Gram-positive, Gram-negative, and anaerobic bacteria.
## Primary Indications
* Complicated intra-abdominal infections
* Complicated skin and skin structure infections
* Community-acquired pneumonia
* Nosocomial pneumonia
* Febrile neutropenia (empiric treatment)
## Adult Dosing
The typical dose is 3.375 grams intravenously (IV) every 6 hours or 4.5 grams IV every 8 hours. Dosing frequency and duration are dependent on the indication, severity of infection, and patient response. Higher doses may be used for severe infections, particularly in critical illness or for suspected difficult-to-treat pathogens, but specific maximums depend on institutional guidelines and the ratio of piperacillin to tazobactam.
## Pediatric Dosing
* **Children < 12 years:** Dosing is typically based on piperacillin component, ranging from 80 to 120 mg/kg/day divided every 6 or 8 hours. The ratio of piperacillin to tazobactam is usually 8:1. Dosing depends on severity of infection and specific indication.
* **Children ≥ 12 years:** Dosing is generally the same as adults.
## Dose Adjustments
* **Renal Impairment (CrCl < 40 mL/min):** Dose reduction is required. Refer to specific product labeling or institutional guidelines for exact dose and frequency adjustments.
* For 3.375 g every 6 hours: Consider 2.25 g every 6 hours or 2 g every 8 hours if CrCl < 20 mL/min.
* For 4.5 g every 8 hours: Consider 3.375 g every 8 hours.
* **Hepatic Impairment:** No dose adjustment is typically required, but caution is advised.
## Contraindications
* Hypersensitivity to piperacillin, tazobactam, other penicillin derivatives, or any component of the formulation.
* History of cholestatic jaundice or hepatic dysfunction associated with prior amoxicillin/clavulanate or piperacillin/tazobactam therapy.
## Adverse Effects
Common adverse effects include diarrhea, nausea, vomiting, rash, headache, insomnia, and injection site reactions. Serious adverse effects include hypersensitivity reactions (anaphylaxis), Clostridioides difficile-associated diarrhea, seizures (particularly with high doses or renal impairment), and hematologic changes (e.g., eosinophilia, leukopenia, thrombocytopenia).
## Key Drug Interactions
* **Probenecid:** May increase and prolong piperacillin serum concentrations.
* **Neuromuscular blocking agents (e.g., vecuronium):** Piperacillin may prolong the action of vecuronium.
* **Warfarin:** Piperacillin may decrease the efficacy of warfarin; increased INR monitoring is recommended.
* **Methotrexate:** Piperacillin may decrease methotrexate levels; increased methotrexate monitoring is recommended.
* **Aminoglycosides:** While often used in combination for synergistic effect, observe for potential antagonism in certain situations, though generally considered safe and effective together for broad-spectrum coverage.
## Monitoring
* Renal function (baseline and periodically, especially in patients with pre-existing renal disease or those receiving nephrotoxic agents).
* Liver function tests.
* Complete blood count (CBC) with differential and platelet count.
* Signs and symptoms of infection.
* Signs of hypersensitivity reactions.
* Signs and symptoms of C. difficile-associated diarrhea.
## Clinical Pearls
* The 3.375 g formulation contains 3 g piperacillin and 0.375 g tazobactam. The 4.5 g formulation contains 4 g piperacillin and 0.5 g tazobactam. The ratio is crucial for efficacy.
* Reconstitution and administration require specific volumes of diluent and appropriate infusion times. Consult product labeling for detailed instructions.
* Duration of therapy is typically 7-14 days, guided by clinical response.
* Consider the spectrum of activity and local resistance patterns when selecting empirical therapy.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information, institutional protocols, and relevant clinical guidelines before making any treatment decisions. Drug information is subject to change.*
